The overall response rate (ORR) for CM patients to ipilimumab, nivolumab, pembrolizumab and atezolizumab is 12%, 40%, 33% and 30% respectively (167169), while the combined treatment of ipilimumab with nivolumab significantly improves the ORR to 61% with median progression-free survival (PFS) of 11.5 months (170, 171)
These products may pose a risk to your health and should not be used
When incorporated into comprehensive research models, MT-2 is frequently evaluated for its effects on melanin production, receptor signaling, and neuroendocrine activity
This action helps control appetite and manage insulin production
If you have additional questions, Thrive Family Practice & Med Spa is here to answer your questions and get you started